Introduction
Actinic keratosis (AK) is a frequent dysplastic skin lesion and its incidence is increasing because of the progressive ageing of the population and the higher cumulative lifetime exposure to ultraviolet light [1] . It is caused by the accumulation of genotoxic DNA damage, and its removal is recommended because of the potential to progress to invasive squamous cell carcinoma [1] .
Several treatment options are available, and the therapeutic decision is based on the careful assessment of the clinical features, among which the number and thickness of the lesions and the clinical aspect of the surrounding skin have a prominent importance. If multiple lesions are present, it is also likely that the keratinocytes of the surrounding sun damaged skin, the so-called field of cancer-ization, harbor genotoxic damages, and therefore treatment approaches aiming to treat the whole area are suggested [1] [2] [3] .
The decision of the optimal strategy may be challenging for the clinician because guidelines [1] [2] [3] place an emphasis purely on clinical efficacy and safety and often do not take into account practical issues, such as the duration of the treatment and time to wound healing, the complexity of the treatment procedure, and the severity of the local skin reaction (LSR), which have great importance for the achievement of the best compliance of patients, particularly if they are elderly or frail [4] , and strongly influence efficacy in real life.
Among treatment options, some approaches, e.g. 5-fluorouracil (5-FU), imiquimod, or DHA (diclofenac plus hyaluronic acid), need a prolonged (1-3 months) treatment cycle, whereas 2 novel approaches allow a much faster treatment: a gel containing ingenol mebutate (IMB) and photodynamic therapy (PDT) with a cream containing methyl aminolevulinate (MAL).
The last 2 therapies have not been directly compared so far, and results from studies against placebo cannot be easily compared because of differences in the primary outcome (total clearance of all of a patient's lesions, number of lesions cleared, or partial participant clearance), time point of efficacy evaluation (most often ranging from 4 to 12 weeks from the end of treatment), and duration of follow-up [4] .
The present study is a nonsponsored, single-center, prospective, open-label, split-face, clinical trial comparing efficacy, safety, LSR, time to wound closure, and patient preference of MAL-PDT versus a gel containing IMB. 
Results
Thirty-five patients were enrolled in the study and completed it in the period from March to June 2015. The main clinical details are described in table 1 .
The 25-cm 2 treated areas harbored a similar total number of AKs (221 with IMB and 216 with MAL-PDT). The density of lesions was similar: 6.31 ± 1.28 in the areas treated with IMB and 6.17 ± 1.22 in the areas treated with MAL-PDT (p = nonsignificant).
MAL-PDT was more painful (Visual Analog Scale: 5.46 ± 3.05 with MAL-PDT vs. 3.74 ± 2.28 with IMB, p < 0.01), whereas skin inflammation was more severe with IMB (LSR score: 11.17 ± 5.29 with IMB vs. 6.69 ± 2.88 with MAL-PDT, p < 0.01). The patients did not experience any other local and systemic, acute or long-term, adverse events related to the treatments. The mean time to wound closure was significantly shorter in lesions with MAL-PDT compared to IMB: 8.20 ± 2.75 versus 12.91 ± 4.86 days, respectively (p < 0.01) ( table 2 ).
As for efficacy, 139 lesions (62.9%) treated with IMB and 145 (67.1%) with MAL-PDT (p = nonsignificant) were cleared after 3 months ( table 2 ) . The average number of lesions per treated area was 2.34 ± 2.40 with IMB and 2.03 ± 1.93 with MAL-PDT. The number of patients with a complete clearance of all treated lesions was 15 (42.9%) with IMB and 11 (31.4%) with MAL-PDT (p = nonsignificant).
The cosmetic outcome was rated as good in 24 patients with IMB and 15 with MAL-PDT and excellent in 11 and 20, respectively (p < 0.05). Scars or hypo-or hyperpigmented areas were never seen ( fig. 2 , 3 ) . Patient preference was in favor of IMB in 14 cases (40%) and MAL-PDT in 21 cases (60%).
Discussion
We found that MAL-PDT was more effective than IMB in the treatment of superficial AKs (Olsen grade I and II) of the face and scalp, but the difference did not reach statistical significance.
The cosmetic outcome was significantly better with MAL-PDT. A possible explanation is that, unlike IMB, MAL-PDT also has well-documented effects against various cosmetic manifestations of chronic photodamage of the skin surrounding AKs [9, 10] . MAL-PDT was more painful, but skin inflammation was more intense and the wound closure process slower with IMB. As the efficacy was not statistically different, it is likely that the better cosmetic outcome and the other treatment features influenced patient preference, which was more often in favor of MAL-PDT. In addition, these findings could help to match treatment features with individual patient's needs with higher satisfaction and effectiveness. Indeed, IMB seems preferable for patients who fear or do not tolerate pain, and MAL-PDT seems preferable for active people with the need of only mild inflammation, fast wound healing, and excellent cosmetic result.
The present investigation has two main limitations. In the first place, we have compared results obtained with a single treatment cycle. However, MAL-PDT is approved for a second treatment session if partial or no remission is seen after 90 days [6] , raising up to 70% the rate of patients with a complete remission of all lesions [4] , whereas IMB is not approved for 2 consecutive treatment cycles [7] , and the degree of the consequent increase of efficacy rate, if any, is unknown. Another limitation is that we is approved only for the treatment of a skin surface of 25 cm 2 [11] . Therefore, the final overall duration of the treatment and time to wound closure is much longer with IMB if skin areas of more than 25 cm 2 are affected because we should deliver consecutive treatment cycles on adjacent skin areas [11] .
MAL-PDT and IMB have been previously compared to placebo in several trials [for review, see 4 ], but only few comparative clinical trials with other active comparators have been reported so far. In comparison to twice-daily application of DHA gel for 90 days, two treatment sessions of MAL-PDT showed a superior efficacy, cosmetic outcome, patients' overall satisfaction, and cost-effectiveness ratio in an open-label, prospective, randomized controlled clinical trial of 200 patients with multiple AKs (total of 1,674 AKs) of the face and scalp [12] .
Four studies have compared MAL-PDT with cryotherapy, reporting a similar efficacy and a higher cosmetic outcome and patient preference [13] [14] [15] [16] . However, they were conducted in patients both with isolated or multiple AKs, and we should be cautious in comparing these findings because, unlike MAL-PDT, cryotherapy is a lesion-directed treatment that is not considered one of the most suitable treatment options for patients with multiple superficial lesions [1] [2] [3] 17] . In the first of these studies [13] , a single MAL-PDT session was delivered, as in the present trial, and the complete remission rate of lesions was similar (68.7%).
In an intraindividual side-to-side comparison of 44 patients, MAL-PDT and imiquimod 5% cream were found equally effective. Pain was associated only with MAL-PDT, whereas the inflammatory reactions were more intense in the imiquimod group. The 2 treatments equally prevented the development of new lesions on the treated fields during a 12-month follow-up period. The overall patient preference was in favor of MAL-PDT in 59.1% of patients and imiquimod in 40.9% [18] .
In an open-label, prospective, randomized, clinical trial, the efficacy and safety of IMB gel (a single application for 3 consecutive days) were compared with 5-FU (2 daily applications for 4 weeks) in the treatment of 100 patients affected by multiple AKs within two 25-cm 2 contiguous fields of the face [19] . The magnitude of the mean highest LSR score was similar, but it peaked at day 4 with IMB and at day 29 with 5-FU. In addition, the LSR score was much more short-lived with IMB. In this study, patient preference was not studied. The authors concluded that the compliance with IMB could be better in the 'real world' because LSRs were of shorter duration and the treatment period was shorter in comparison to 5-FU [19] .
In conclusion, the present split-face randomized trial was helpful for a better knowledge not only of efficacy and safety but also of cosmetic outcome, pain, LSR, time to wound healing, and patient preference [4, 20] . These issues have a strong impact on the adherence of patients (particularly if they are elderly or frail) to the treatment, and therefore they can influence to a large extent the effectiveness of a treatment in 'real life' [18] . In addition, the present results may help to identify which therapy may be more suitable for a given subset of patients.
